Skip to content

Study · Ex vivo tissue · mouse · 2018

3 results

A mitochondrial-targeted antioxidant improves myofilament Ca2+ sensitivity during prolonged low frequency force depression at low PO2.

Gandra PG, Shiah AA, Nogueira L, Hogan MC

The Journal of physiology11 Feb 2018Cited by 21 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueEfficacy outcome

    In intact mouse muscle fibres at low PO2, SS31 treatment led to less impairment of submaximal force development 30 min after fatiguing contractions than no treatment.

    In plain wordsIn mouse muscle fibres, SS31 reduced the loss of force after fatigue compared with untreated fibres.

    Outcome
    IncreaseSubmaximal force development 30 min after fatigue
    Study

    mousen: not reported in source

    Intact single muscle fibres at PO2 of about 5 Torr
    Comparator
    Untreated fibres
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After 30 min following the end of the fatiguing contractions, fibres treated with SS31 showed significantly less impairment in force development compared to untreated fibres at submaximal frequencies of stimulation.
    1 context sentence
    Summary · context
    We treated intact single fibres from mice with the mitochondrial-specific antioxidant SS31, and measured force development and intracellular [Ca2+ ] 30 min after fatigue at an extracellular PO2 of ∼5 Torr.
  2. 02LabEx vivo tissueMechanism

    In intact mouse muscle fibres, peak cytosolic Ca2+ transients decreased equally in SS31-treated and untreated fibres after fatigue.

    In plain wordsIn mouse muscle fibres, calcium peaks fell by the same amount with and without SS31.

    Outcome
    No significant changePeak cytosolic Ca2+ transients
    Study

    mousen: not reported in source

    Intact single muscle fibres at PO2 of about 5 Torr
    Comparator
    Untreated fibres
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The cytosolic peak [Ca2+ ] transients (peak [Ca2+ ]c ) were equally decreased in both groups compared to pre-fatigue values.
    1 context sentence
    Summary · context
    We treated intact single fibres from mice with the mitochondrial-specific antioxidant SS31, and measured force development and intracellular [Ca2+ ] 30 min after fatigue at an extracellular PO2 of ∼5 Torr.
  3. 03LabEx vivo tissueMechanism

    In intact mouse muscle fibres, myofibrillar Ca2+ sensitivity was unaltered in SS31-treated fibres but diminished in untreated fibres after fatigue.

    In plain wordsIn mouse muscle fibres, SS31 kept muscle calcium sensitivity from falling after fatigue, unlike untreated fibres.

    Outcome
    IncreaseMyofibrillar Ca2+ sensitivity 30 min after fatigue
    Study

    mousen: not reported in source

    Intact single muscle fibres at PO2 of about 5 Torr
    Comparator
    Untreated fibres
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The combined force and peak [Ca2+ ]c data demonstrated that myofibrillar Ca2+ sensitivity was diminished in the untreated fibres 30 min after fatigue compared to pre-fatigue values, but Ca2+ sensitivity was unaltered in the SS31 treated fibres.
    1 context sentence
    Summary · context
    We treated intact single fibres from mice with the mitochondrial-specific antioxidant SS31, and measured force development and intracellular [Ca2+ ] 30 min after fatigue at an extracellular PO2 of ∼5 Torr.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.